Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
β-Lactamase inhibitors: what you really need to know.
Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B. Ambrose PG, et al. Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Curr Opin Pharmacol. 2017. PMID: 29096172 Review.
Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN; SENTRY Antimicrobial Surveillance Program. Bhavnani SM, et al. Among authors: ambrose pg. Diagn Microbiol Infect Dis. 2006 Mar;54(3):231-6. doi: 10.1016/j.diagmicrobio.2005.09.011. Epub 2006 Jan 19. Diagn Microbiol Infect Dis. 2006. PMID: 16423491
New EMA guideline for antimicrobial development.
Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL. Ambrose PG, et al. Lancet Infect Dis. 2012 Apr;12(4):265-6. doi: 10.1016/S1473-3099(12)70046-4. Lancet Infect Dis. 2012. PMID: 22459079 No abstract available.
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. Dudley MN, et al. Among authors: ambrose pg. Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18. Clin Infect Dis. 2013. PMID: 23334813 Review.
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. VanScoy B, et al. Among authors: ambrose pg. Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29. Antimicrob Agents Chemother. 2013. PMID: 23629705 Free PMC article.
Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG. Vanscoy B, et al. Among authors: ambrose pg. Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17. Antimicrob Agents Chemother. 2013. PMID: 23774429 Free PMC article.
178 results